Upregulation of GLS expression promotes glutamine depletion in tumor cells, leading to HIF-1α activation and IL-23 secretion by TAMs, which can inhibit the tumor-killing effect of cytotoxic lymphocytes (153). This evidence concerns the gene HIF1A and neoplasm.